This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
KROS Turns to Next Wave of TGF-Beta Muscle Therapies
by Ahan Chakraborty
Keros is shifting toward rinvatercept-led neuromuscular development, with phase II plans, early human signals and cash runway shaping the KROS story.
SRPTPositive Net Change PTCTPositive Net Change KROSNegative Net Change
biotechnology biotechs medical pharmaceuticals
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
by Ahan Chakraborty
Keros heads into 2026 with rinvatercept catalysts in DMD and ALS as investors watch phase II plans, orphan status and early clinical signals.
SRPTPositive Net Change PTCTPositive Net Change KROSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
by Ahan Chakraborty
Keros faces a volatile setup after its Q1 miss, with a longer cash runway and leaner costs balanced against uncertain milestone-driven revenue.
SRPTPositive Net Change PTCTPositive Net Change KROSNegative Net Change
biotechnology biotechs medical pharmaceuticals
LLY Reports Third Phase III Win for Next-Generation Obesity Drug
by Zacks Equity Research
Eli Lilly's retatrutide delivers its third phase III win, showing up to 28.3% weight loss at 80 weeks and broader gains across obesity-related measures.
NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?
by Kinjel Shah
JNJ's diversified pharma and MedTech growth, pipeline progress and stronger 2026 outlook give it an edge over PFE.
JNJNegative Net Change PFEPositive Net Change PTGXNegative Net Change
pharmaceuticals
AGEN Stock Dips 19.4% in a Month: Time to Buy, Hold or Sell?
by Sundeep Ganoria
Agenus' shares slide after weak Q1 results, but BOT/BAL phase III progress, survival data and Zydus backing keep long-term growth hopes alive.
BMYPositive Net Change MRKNegative Net Change AGENPositive Net Change
biotechs medical pharmaceuticals
BAYRY's Kerendia Label Expansion Application Gets Priority Review
by Zacks Equity Research
Bayer wins FDA Priority Review for Kerendia label expansion in CKD tied to type I diabetes after strong phase III data.
REGNNegative Net Change JNJNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Johnson & Johnson, Oracle, Netflix and Espey
by Zacks Equity Research
JNJ, ORCL and NFLX headline top Zacks research reports as cloud growth, drug launches and ad expansion drive focus.
JNJNegative Net Change NFLXNegative Net Change ORCLPositive Net Change ESPNegative Net Change
aerospace computers consumer-discretionary pharmaceuticals
Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?
by Ahan Chakraborty
Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining traction across obesity, diabetes and related markets.
NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know
by Zacks Equity Research
Atara stock soars 82% as the FDA outlines a regulatory pathway for its lead product candidate, tab-cel, reviving hopes for potential U.S. approval, after two prior CRLs.
ATRANegative Net Change LQDANegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals